Phentermine
Adipex-p, Ionamin, Lomaira, Phentermine, Qsymia (phentermine) is a small molecule pharmaceutical. Phentermine was first approved as Fastin on 1982-01-01. It is used to treat obesity in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Adipex-p, Phentermine (discontinued: Adipex-p, Fastin, Ionamin, Obestin, Oby-trim, Phentermine, Phentermine resin complex, Suprenza, Tora, Wilpo)
CombinationsPhentermine topiramate, Qsymia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phentermine hydrochloride
Phentermine hydrochloride
+
Topiramate
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adipex-p | ANDA | 2024-09-03 |
| lomaira | ANDA | 2023-12-19 |
| phentermine | ANDA | 2024-04-26 |
| phentermine hcl | ANDA | 2024-10-15 |
| phentermine hcl c-iv | ANDA | 2022-07-25 |
| phentermine hcl c-iv phentermine hydrochloride | ANDA | 2023-04-12 |
| phentermine hydrochloride | ANDA | 2024-11-04 |
| phentermine resin | ANDA | 2017-04-07 |
| qsymia | New Drug Application | 2024-10-03 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PHENTERMINE HYDROCHLORIDE / TOPIRAMATE, QSYMIA, VIVUS | |||
| 2025-06-24 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
74 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 11 | 8 | 17 | 8 | 48 |
| Overweight | D050177 | — | E66.3 | — | 3 | — | 5 | 3 | 11 |
| Weight loss | D015431 | HP_0001824 | — | 1 | 2 | — | 2 | 3 | 8 |
| Pediatric obesity | D063766 | — | — | 1 | 3 | 1 | 2 | — | 7 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 2 | 1 | 1 | 1 | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 2 | 1 | — | 4 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | 3 | — | 1 | — | 4 |
| Bariatric surgery | D050110 | — | — | — | 2 | — | 1 | — | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | 1 | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | 1 | — | 1 | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | — | 1 | — | — | 1 |
| Urinary calculi | D014545 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | — | 3 |
| Bulimia | D002032 | — | F50.2 | 1 | 1 | — | — | — | 2 |
| Feeding and eating disorders | D001068 | — | F50 | 1 | 1 | — | — | — | 2 |
| Binge-eating disorder | D056912 | — | F50.2 | 1 | 1 | — | — | — | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | — | — | 1 | 2 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | — | — | 1 |
| Nephritis | D009393 | — | N05 | — | 1 | — | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 3 | — | — | — | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | 1 | — | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 2 | 2 |
| Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
| Diet therapy | D004035 | — | — | — | — | — | — | 1 | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
| Severe acute malnutrition | D000067011 | — | — | — | — | — | — | 1 | 1 |
| Pancreatitis | D010195 | HP_0001733 | K85 | — | — | — | — | 1 | 1 |
| Enteral nutrition | D004750 | — | — | — | — | — | — | 1 | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Phentermine |
| INN | phentermine |
| Description | Phentermine is a primary amine. It has a role as a dopaminergic agent, an adrenergic agent, a sympathomimetic agent, an appetite depressant, a central nervous system stimulant and a central nervous system drug. It is a conjugate base of a phentermine(1+). |
| Classification | Small molecule |
| Drug class | Appetite suppressant |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(N)Cc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 122-09-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1574 |
| ChEBI ID | 8080 |
| PubChem CID | 4771 |
| DrugBank | DB00191 |
| UNII ID | C045TQL4WP (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Qsymia – Vivus
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Phentermine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,924 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
40,203 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use